Contact Us

Life Sciences

Introduction: From Proof-of-Concept to Enterprise Performance

Across the Process Industries, Artificial Intelligence (AI) has evolved from an emerging idea to a proven driver of efficiency and insight. Leading organizations have demonstrated that AI can predict equipment failures, optimize energy use, and improve plant reliability. Yet for most, these achievements remain trapped within pilot programs, valuable in isolation but limited in scale. 

The true opportunity lies in translating these local proofs into enterprise-wide performance. Doing so requires more than algorithms; it demands structure, governance, and a deep connection between data, operations, and financial outcomes. Only then can AI move from the lab to the control room and from experimentation to measurable enterprise value. 

The Challenge:Why AI Pilots Stall Before Scale

Despite significant investment, most industrial AI initiatives remain confined to the pilot stage. A recent study found that 74% of companies say they struggle to scale AI and turn pilots into full-value operations. This highlights a persistent gap between proof-of-concept success and enterprise-level impact — a challenge that continues to constrain digital transformation across the Process Industries.

Several structural challenges explain why:

Siloed data and infrastructure

Operational data (OT), maintenance systems, and enterprise IT remain fragmented, limiting visibility and preventing a unified operational view.

Limited interoperability

AI models developed in isolation often fail to connect seamlessly with plant control systems (DCS/APC) or data historians.

Undefined value metrics

Many pilots focus on model accuracy rather than business outcomes such as yield, energy efficiency, or uptime.

Lack of ownership or lack of a practical companywide AI implementation plan

Without clear governance or accountability, AI efforts remain in academic experiments rather than operational tools.

The outcome is predictable — dozens of isolated AI initiatives that look promising on paper but fail to move the EBIT needle in any meaningful way.

A Composite Scenario: From Isolated Success to Scalable Impact

These structural challenges—where operational, maintenance, and enterprise IT data remain trapped in isolated silos, and AI models are unable to interoperate with foundational systems like DCS, APC, and plant historians—surface in operations as fragmented intelligence, uneven performance, and a systemic inability to propagate successful pilots across the enterprise.

Recognizing this fragmentation, it is important to set a clear objective: to build a unified AI framework that could deliver reliability and profitability at scale.

To support this shift, we use mcube™, TCG Digital’s Integrated AI Platform, which acts as a common intelligence layer across plants. At its core is an ontology-driven semantic layer that gives every data element—from sensor tags to lab results—a consistent, unambiguous meaning. By mapping all incoming data to a canonical vocabulary, mcube™ creates a unified knowledge graph that strengthens governance and ensures AI models operate on trusted, context-rich information.

Building on this semantic foundation, mcube™ serves as an autonomous AI fabric that layer intelligence over existing systems without requiring rip-and-replace modernization. It continuously integrates and contextualizes data from DCS/APC, historians, LIMS, ERP, EAM, and MIS, combining real-time and batch inputs into a single, actionable view of operations. Its data-source-agnostic design allows seamless connectivity with any IT or OT system, bridging gaps between operations, maintenance, and business functions.

mcube™ supports traditional machine learning, hybrid physics-ML models, generative AI, and agentic AI for decision support and autonomous action. Secure, standardized interfaces ensure that the platform enhances existing digital investments while progressively adding intelligence across sites. Deployable on cloud, on-premises, or hybrid environments, mcube™ provides scalable governance and democratized access to insights, enabling plants to transition from reactive operations to predictive and prescriptive performance—ultimately improving reliability, energy efficiency, and profitability.

Evolving Metrics: From OEE to Financially Linked Performance Indicators

While unified data and interoperability address the technical barriers to scaling AI, success ultimately depends on measuring what truly drives enterprise value. OEE has long been the standard for plant performance, but it reflects equipment efficiency—not margin improvement, financial risk reduction, or EBIT contribution. In today’s environment of volatile energy costs, variable feedstocks, and increasing reliability demands, OEE offers only a partial view.

To scale AI beyond isolated pilots, organizations must shift toward EBIT-linked performance metrics that capture real financial impact. Metrics such as EBIT per unit of throughput, cost-to-serve by product grade, predictive reliability value, energy margin contribution, adaptability to market conditions, and carbon intensity per EBIT dollar reveal how operational decisions influence profitability and resilience.

Just as importantly, AI pilots must be evaluated against these financially grounded KPIs. Without this alignment, pilots may show technical improvement without demonstrating business value.

When plants measure outcomes through an EBIT-focused lens, AI moves from experimentation to a scalable driver of margin growth and operational excellence.

A Structured Path to Scalable AI: From Pilot to Autonomy in 90 Days

Resolving the technical fragmentation is only half the challenge — organizations also need a clear, disciplined path that builds ownership, governance, and workforce readiness to ensure AI scales. The journey from pilots to autonomous operations begins not with machines, but with mindsets. While technology defines what’s possible, it is people — their decisions, discipline, and collaboration — that determine what scales. For most organizations, the first 90 days represent the critical inflection point between experimentation and execution. It’s the period where vision becomes action — aligning leadership, enabling the workforce, and embedding AI into the rhythms of daily plant performance. TCG Digital helps enterprises navigate this transition through a structured 90-day roadmap designed to accelerate progress toward self-optimizing operations. The approach blends strategic alignment, AI enablement, and human transformation — ensuring that every technical milestone is matched by organizational readiness and measurable business value.

TCG Digital works alongside clients and their AI partners to connect strategy with execution:

  • Leadership Alignment:

    Executive workshops to unite business vision with operational priorities.

  • Data & Pilot Readiness:

    Joint maturity scans, pilot selection, and success metric definition.

  • Workforce Enablement

    Training programs and copilots that empower operators with AI-assisted decision-making.

  • Integration & Governance

    Linking pilot workflows with plant control systems under supervised automation, supported by MLOps frameworks for model monitoring and retraining.

  • Change Management

    Preparing teams for human-in-the-loop autonomy through continuous coaching and KPI-linked incentives.

  • Executive Review:

    Consolidating results, measuring impact, and setting up a 6–12 months roadmap for scaled deployment.

Conclusion: The Path Forward

Industrial AI has reached an inflection point. The real differentiator is the capability to scale with intent — bringing data, intelligence, and people together under a unified operational vision. Success comes from structured execution that connects technology with measurable business impact.

We help enterprises make this transformation real — embedding AI into the fabric of plant operations, control systems, and decision-making. The outcome is a smarter, more resilient operation that continuously learns, adapts, and optimizes performance.

The path forward is clear: move beyond pilots, scale with purpose, and let AI drive sustainable, enterprise-wide value.

In today’s rapidly evolving bio-pharma industry, delivering high-quality drugs efficiently while maintaining compliance is a critical challenge. From managing variability in manufacturing processes, to addressing data silos that increase operational costs, these issues demand innovative solutions.

We are addressing these hurdles with mcube™ by TCG Digital, an advanced Data & AI platform designed to optimize operations, break down silos, and drive higher margins.

Download Brochure

Introduction:
Reliability Beyond Conventional Predictive Maintenance

In asset-intensive industries such as refining, petrochemicals, and continuous processing, the financial, safety, and reputational implications of unplanned downtime are significant. Traditional predictive maintenance systems have improved reliability, yet they often fall short in critical areas:

  • Weak signals of failure are missed until they escalate into major incidents.
  • Operators face alert fatigue from excessive, non-prioritized notifications.
  • Troubleshooting relies heavily on manual fault tree analysis, extending recovery times.
  • Maintenance planning is decoupled from financial impact, limiting business alignment.

A leading petrochemical operator confronted precisely these issues within its high-pressure (HP) and depressurized (DP) operations. The organization required a framework that not only detected anomalies but also contextualized risks, accelerated resolution, and linked reliability directly to business outcomes.

The Challenge

The operator’s monitoring systems produced vast amounts of data but lacked the intelligence to distinguish critical events from background noise. Failures within HP instrumentation and DP process systems frequently progressed unnoticed until they triggered costly outages.

The core challenges were:

knowledge.png
Delayed or no anomaly detection in complex mechanical and process domains.
rocket.png

Unclear alert prioritization, leading to resource misallocation.

moniter.png

Manual, time-intensive root cause analysis that slowed recovery.

financial.png

Limited financial visibility, making it difficult to align reliability initiatives with business priorities.

The Reliable AI Intervention

To address these challenges, the operator deployed Reliable AI, an agentic framework leveraging Generative AI and Large Language Models (LLMs). The solution integrated anomaly detection, predictive modeling, and intelligent retrieval to provide actionable, plant-specific insights.

The following framework illustrates how Reliable AI was applied across HP and DP operations to detect anomalies and generate actionable insights.

How GenAI Strengthened Reliability

From unstructured data to insights

Maintenance logs, operator shift notes, and incident reports were ingested by LLMs, transforming unstructured text into structured signals that complemented sensor data.

Contextual diagnostics

GenAI connected new anomalies with past incidents, highlighting likely causes and recommended fixes based on plant-specific history.

Adaptive learning loop

As engineers validated or rejected AI recommendations, the model continuously refined its accuracy, improving predictive reliability over time.

Natural-language interaction

Engineers could query the system in everyday language “Show me previous DP compressor failures with similar vibration patterns” and receive precise, context-aware answers.

Key components included

Anomaly Detection

Isolation Forest models continuously monitored HP and DP units to detect subtle deviations in real time.

RAG-Based Retrieval

Plant-specific historical incidents and resolutions were embedded into the model, allowing rapid recall of relevant precedents.

Financial Overlay

Reliability risks were evaluated not only technically but also in terms of cost, downtime impact, and production losses.

Predictive Modeling with Tagged Data

Systematic use of historical attributes (anomaly status, cause, temporary and permanent fixes) enabled forecasting of failures.

Automated Fault Tree Traversal

The AI streamlined diagnostic workflows, significantly reducing time-to-resolution.

The Results

Within six months of deployment, the operator achieved measurable and business-critical improvements across its HP and DP operations.

These outcomes demonstrated that the integration of GenAI-driven intelligence into reliability workflows improved operational stability, safety, and financial performance simultaneously.

Strategic Implications

Building on the success of the initial deployment, the operator is extending Reliable AI across additional facilities, embedding reliability as a core driver of operational performance. The broader implications are both immediate and forward-looking:

Operational Relevance

Plant-specific insights reduced downtime and alert fatigue, proving that GenAI can be integrated into daily engineering workflows without overwhelming operators.

Business Alignment

By overlaying financial metrics on reliability risks, maintenance actions were directly tied to profitability, capital efficiency, and risk reduction.

Autonomous Reliability Agents

Future versions will be capable of executing routine maintenance decisions with minimal human intervention.

Deeper Financial Integration

Asset reliability metrics will be directly correlated with profitability, risk exposure, and shareholder value.

Cross-Sector Scalability

The framework shows strong applicability in power, utilities, and discrete manufacturing, extending benefits beyond petrochemicals.

Evolving Engineering Roles

As automation reduces routine analysis, engineers will shift from reactive troubleshooting to proactive optimization and reliability strategy.

Interested in what lies ahead? You can watch our webinar, “Case Discussion: Asset Reliability and Operational Excellence using Gen-AI and AI in Process Industries,” on demand. Register to access the full recording and explore these future developments in detail.

Register here

Conclusion

The case of this petrochemical operator underscores how Reliable AI redefines predictive maintenance. By bridging anomaly detection, contextual reasoning, and financial visibility, the framework reduced downtime, optimized maintenance, and strengthened safety.

This demonstrates that the future of plant reliability lies not in more data or dashboards, but in intelligent, adaptive systems that augment human expertise with real-time, context-rich, and business-aligned guidance.

Reliable AI moves beyond monitoring, providing a practical framework for achieving higher reliability and operational resilience.

Whitepaper Overview

This whitepaper focuses on optimizing laboratory performance by leveraging advanced technologies like automation, data analytics, and AI. It highlights strategies for improving efficiency, accuracy, and decision-making in lab operations to enhance research outcomes and productivity.

Download Whitepaper

Whitepaper Overview

This whitepaper discusses methods for sample analysis and validation in bioassays, emphasizing the importance of precision and accuracy in experimental procedures. It explores key validation parameters, including sensitivity, reproducibility, and robustness, to ensure reliable results in biological testing.

Download Whitepaper

Whitepaper Overview

This whitepaper explores the “Lab of the Future” concept, focusing on how advanced technologies like AI, robotics, and data analytics can revolutionize laboratory environments. It highlights the benefits of automation, real-time data access, and predictive modeling in improving operational efficiency, research accuracy, and decision-making in labs.

Download Whitepaper

Whitepaper Overview

This whitepaper explores the potential of sample clinical trials in accelerating drug development. It highlights how advanced analytics, data integration, and AI can improve trial design, patient recruitment, and decision-making in clinical research, ultimately enhancing the success rates of trials and speeding up time-to-market for new treatments.

Download Whitepaper

Introduction


In the world of clinical trials, data is at the heart of the quest for safer and more effective treatments. However, as trials grow in scale and complexity, the data they generate from various sources has surged to unprecedented levels. Traditional data management methods are no longer sufficient for efficiently handling this deluge. This is where robust data management systems step in, playing a pivotal role in modern clinical trial success.

Historically, clinical data management relied on fragmented, manual processes and isolated data silos. Yet, in today’s data-driven landscape, where trials generate vast and diverse datasets, this approach no longer holds. Modern trials demand a shift towards advanced data management solutions.

Centralized cloud-based data management systems

Enterprises are increasingly adopting centralized, cloud-based data management systems to meet these challenges. These systems serve as the central hub for data, offering a unified platform for seamless data integration. This integration fosters collaboration and facilitates real-time data access and analysis.

Enhancing efficiency through automation


Automation is another game-changing aspect of data management systems. By automating routine tasks like data entry and validation, these systems enhance efficiency, ensure data consistency, and expedite data management. In clinical trials, where data accuracy is paramount, automation is a game-changer.

Ensuring Data Quality and Compliance

Standardization and governance are crucial components of modern data management. Standardization ensures consistent data collection across sites and trials, simplifying comparisons and analysis. Governance, meanwhile, guarantees compliance with regulations and data security standards, safeguarding patient confidentiality and trial integrity.

Harnessing Real-Time Insights

One of the most transformative features of modern data management systems is their ability to provide real-time analytics. Researchers and sponsors can access and analyze data as it is generated, enabling swift, informed decisions. This empowers them to refine protocols, optimize patient recruitment, and accelerate therapy development.

In conclusion, data management systems are now indispensable in clinical trials. They not only streamline data processes but also unlock data’s full potential. As trials become increasingly data-centric, these systems are pivotal in advancing medical research, ensuring data accuracy, and contributing to innovative treatments. In an era where data holds paramount importance, data management systems stand as the cornerstone of clinical research.

Introduction

In the world of clinical trials, achieving real-time end-to-end visibility has become more than just a trend; it’s a critical necessity. Modern clinical trials are complex endeavors involving numerous stakeholders, generating massive amounts of data that reside in disparate systems. To navigate this complexity and make informed decisions, pharmaceutical companies are turning to advanced data analytics and customized visual dashboards.

The Demand for End-to-End Visibility

Clinical trials are no longer isolated studies but rather complex ecosystems involving pharmaceutical companies, research organizations, regulatory bodies, and healthcare professionals. Each trial generates vast datasets, from patient recruitment to safety monitoring, often residing in isolated databases. This fragmentation creates blind spots and hampers decision-making.

However, end-to-end visibility is more than data integration; it’s about having a comprehensive view of the entire clinical trial landscape. This approach empowers stakeholders at all levels to proactively identify risks, refine strategies, and make data-driven decisions in real time.

The Power of Advanced Data Analytics

At the core of achieving end-to-end visibility is advanced data analytics. These tools can process large datasets, analyze intricate relationships, and extract valuable insights. Sophisticated algorithms and statistical models can predict potential issues, improving resource allocation and patient safety.

For instance, predictive analytics can forecast patient recruitment rates, while machine learning algorithms can detect adverse events early. These capabilities are vital as clinical trials become more global and complex.

Customized Visual Dashboards: A Window into Insights

Customized visual dashboards are more than just data presentation tools; they are the windows through which sponsors gain real-time access to invaluable insights. These user-friendly interfaces provide dynamic displays of complex data, offering real-time updates and customizable views. What sets them apart is their ability to enable sponsors to break down data silos and synthesize massive volumes of disparate data points into one single source of truth that reveals actionable insights. This breakdown of data silos fosters collaboration, enhances transparency, and empowers stakeholders at all levels to make data-driven decisions with confidence.

Imagine a clinical trial manager tracking patient enrollment on a real-time dashboard, while a safety officer monitors adverse events on the same platform. Customization ensures stakeholders see precisely what they need to make informed decisions.

The Future of Clinical Trials: Data-Driven Visibility

The future of clinical trials revolves around data-powered, end-to-end visibility. The benefits are compelling: shorter timelines, enhanced patient safety, cost reduction, and better decision-making. Regulatory bodies are also beginning to support the use of advanced analytics and dashboards in clinical trials.

In conclusion, achieving end-to-end visibility in clinical trials is not just a possibility; it’s a necessity in today’s complex pharmaceutical landscape. By leveraging advanced data analytics and customized visual dashboards, sponsors can confidently navigate modern trial challenges. The organizations that embrace this data-driven paradigm will lead the way in medical innovation.

Introduction


Patient recruitment in clinical trials has long been a challenging and time-consuming process, causing delays and increasing costs. Clinical trials come with stringent eligibility criteria, and potential participants often have reservations about safety, the time commitment required, or a simple lack of awareness about available trials. However, the advent of artificial intelligence (AI) is poised to revolutionize patient recruitment, offering a more efficient, cost-effective, and patient-centric approach.

The Power of AI in Clinical Trial Recruitment

AI has the potential to analyze vast amounts of data from various sources, including electronic health records, claims data, and registries, to identify patients who meet the complex eligibility criteria for clinical trials. Additionally, AI can help match patients to trials that best align with their individual needs and preferences, offering a win-win scenario for both patients and trial sponsors.

Addressing Inefficient Patient Recruitment

AI’s ability to analyze both structured and unstructured patient data from diverse sources is a game-changer for clinical trial recruitment. This technology can identify eligible candidates who meet complex inclusion and exclusion criteria. For example, a study published in the Nature Digital Medicine journal in 2023 demonstrated that AI-powered patient recruitment can reduce costs by up to 70% and accelerate clinical trials by up to 40%. This efficiency in patient recruitment not only benefits the trial sponsors but also enables quicker access to potentially life-saving treatments for patients.

Customized Visual Dashboards: A Window into Insights

Customized visual dashboards are more than just data presentation tools; they are the windows through which sponsors gain real-time access to invaluable insights. These user-friendly interfaces provide dynamic displays of complex data, offering real-time updates and customizable views. What sets them apart is their ability to enable sponsors to break down data silos and synthesize massive volumes of disparate data points into one single source of truth that reveals actionable insights. This breakdown of data silos fosters collaboration, enhances transparency, and empowers stakeholders at all levels to make data-driven decisions with confidence.

Imagine a clinical trial manager tracking patient enrollment on a real-time dashboard, while a safety officer monitors adverse events on the same platform. Customization ensures stakeholders see precisely what they need to make informed decisions.

Overcoming the Diversity Challenge

One of the persistent challenges in clinical trial recruitment has been limited diversity, particularly in underrepresented minority populations. AI can help address this issue by optimizing recruitment through network analysis. By doing so, it ensures that trials, especially those focused on rare diseases, have diverse and representative participant pools. This, in turn, leads to more generalizable treatment outcomes and a broader understanding of the trial’s impact on different demographics.

Reducing High Dropout Rates

High patient dropout rates, which can be as high as 30%, have been a significant issue in clinical trials. These dropouts not only lead to unreliable results but also cost overruns for trial sponsors. AI can mitigate this problem by effectively matching patients to trials, reducing the burden of manual screening. Furthermore, AI’s continuous engagement with patients can help minimize dropouts and improve participant retention, resulting in more robust and reliable data.

Enhancing Data Utilization and Site Selection

In many cases, patient data remains underutilized, missing out on potential recruits for clinical trials. AI addresses this issue by increasing identification rates by up to 50% through enhanced data utilization. Moreover, it can analyze enrollment patterns to optimize site selection and recruitment strategies, ensuring the most efficient use of resources.

AI’s Transformation of Clinical Trials

Artificial intelligence is ushering in a new era for clinical trials by making them more accessible, faster, economical, and patient-focused. It smartly leverages data to match patients to trials efficiently, benefiting both patients and trial sponsors.

One notable solution leading this transformation is TCG Digital’s TrialXch, an AI-powered platform revolutionizing clinical trial recruitment. TrialXch utilizes AI to efficiently match patients to appropriate trials by analyzing complex health data. By optimizing the identification of eligible candidates, site selection, enhancing diversity, reducing dropout rates, and ensuring regulatory compliance, TrialXch is making clinical trial recruitment more accessible, swift, cost-effective, and patient-focused. Ultimately, it benefits all stakeholders involved in clinical trials, furthering the advancement of medical science and improving patient access to innovative treatments.

In conclusion, artificial intelligence is reshaping the landscape of clinical trial recruitment, addressing age-old challenges such as delays, high costs, limited diversity, and dropouts. This innovative technology promises to usher in a new era of patient-centric and efficient clinical trials, bringing us closer to breakthroughs in healthcare and treatments that can benefit us all.